Cosmo Pharmaceuticals N.V.

$ 68.50 3.01 %

Cosmo Pharmaceuticals N.V. operates as a specialized biopharmaceutical firm, primarily focused on the global development and commercialization of treatments and diagnostic tools within the gastroenterology and endoscopy fields. Its product lineup includes oral tablet formulations like Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, which are prescribed to achieve remission in cases of active, mild to moderate ulcerative colitis. The company also pioneers innovative diagnostic solutions such as GI Genius, an artificial intelligence-driven system designed to enhance the detection of colorectal polyps, and Methylene Blue MMX, a diagnostic drug that improves the visibility of pre-cancerous and cancerous colorectal lesions during colonoscopy procedures. For gastrointestinal endoscopic interventions, Cosmo provides Eleview, an injectable composition used to facilitate the submucosal lift of polyps, adenomas, early-stage cancers, and other mucosal lesions. Beyond its core GI offerings, the company's portfolio extends to Aemcolo/Relafalk, a pharmaceutical indicated for traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth. In the dermatological space, it offers Winlevi, an androgen receptor inhibitor for the treatment of acne vulgaris. Further developments encompass Clascoterone, another androgen receptor inhibitor targeting androgenetic alopecia on the scalp; Rifamycin for irritable bowel syndrome with diarrhea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent employed for procedural sedation; CB-03-10, an oral androgen receptor antagonist under investigation for solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a unique single-use enema formulation. Cosmo Pharmaceuticals N.V. has established licensing agreements with partners including RedHill Biopharma Ltd. and Acacia Pharma Group plc. The company was founded in 1997 and its corporate headquarters are located in Dublin, Ireland.

CEO: Giovanni Di Napoli - https://www.cosmopharma.com

Price objectif

-

Recommandation

-

DCF

$ 25.16

Loading data...

COPN.SW vs S&P500

Loading data...

No data available.

Quick ratio

6.77

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-326.19

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.21

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-0.77 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-0.97 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

11.18

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.01

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.00

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-899.04 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
8.60 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.19 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.